Phase 2 (Data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: JTX-4014 for Metastatic Non-small cell lung cancer (NSCLC) - Phase 2 Data
ClinicalTrials.gov (NCT04549025): Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (SELECT)
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
JTX-4014 is a well-characterized fully human IgG4 monoclonal antibody designed to block binding to PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates. Jounce completed enrollment in the Phase 1 clinical trial of JTX-4014.
Updated by HC
JNCE, Metastatic Non-small cell lung cancer (NSCLC) , JTX-4014
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post